Radiation after prior CAR T for relapsed multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests giving “salvage” radiation (radiation meant to control remaining cancer) after you’ve already had BCMA CAR-T therapy for multiple myeloma. It’s for people whose PET or other scan still shows active myeloma at least 30 days after CAR-T, and who have a spot that radiation can target.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older when you sign consent
- Have a diagnosis of multiple myeloma
- Have already received BCMA CAR-T therapy as standard treatment
- After CAR-T, have a PET or other scan showing active disease on day 30 or later
- Have at least one myeloma spot (in bone or soft tissue) that doctors can treat with radiation
- Be able to understand the study and sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This trial tests a new type of CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is for people whose multiple myeloma has come back or not responded after at least three prior treatments.
This trial tests whether giving BCMA-targeting CAR-T cells after a stem cell transplant can help treat newly diagnosed multiple myeloma. It is for people who are healthy enough for both procedures.
This early trial tests a new CAR-T cell treatment targeting three proteins (CD19, CD22, and BCMA) on myeloma cells. It's for people whose myeloma came back or didn't respond to at least three prior treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.